Sellas Life Sciences Extends Runway to $135.8M, Regal AML Trial Hits 78 of 80 Events
SLS•Sellas Life Sciences increased cash reserves to $135.8 million after receiving $28.7 million from warrant exercises, extending its capital runway for upcoming clinical trials. Its late-stage AML Regal trial has logged 78 of the 80 events needed for final analysis, potentially signaling stronger patient survival outcomes.
1. Cash Runway Expansion
As of March 31, 2026, cash and equivalents stood at $107.1 million and the company has secured $28.7 million from warrant exercises in April and May, boosting its cash position to $135.8 million. CEO Angelos Stergiou said this extended runway will fund strategic milestones and therapeutic program progression.
2. Late-Stage AML Regal Trial
The late-stage Regal trial of Galinpepimut-S in AML has recorded 78 of the 80 events required for final analysis nearly 25 months after enrollment completion, suggesting patients may be surviving longer than projected. This extended duration could signal positive efficacy trends for the therapy’s potential approval path.
3. Upcoming SLS009 Phase 2 Data
Investors are anticipating Phase 2 data for SLS009 in AML later this year, which could catalyze valuation revisions depending on safety and efficacy outcomes.
4. Stock Reaction and Outlook
Shares dipped approximately 2.5% following the warrant exercise news before retail sentiment shifted to bullish comments emphasizing the importance of clinical readouts. Continued trial updates and capital management are expected to drive share performance through the remainder of 2026.
